Keywords: momenta, pharma, sets, priority, launch, m-enoxaparin, losses
Momenta Pharma sets priority on launch of M-Enoxaparin, as losses narrow
Article | 07 April 2008
The US biotechnology industry includes about 1,000 firms, with combined annual revenue close to $50.0 billion. Rapid advances in the sector mark ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
